News Search Results
Sep 16, 2025, 07:00 ET Dualitas Launches With $65 Million Series A to Advance Novel Bispecific Antibody Pipeline in Immune and Inflammatory Disease
compelling activity that monospecific agents cannot achieve. About Dualitas Therapeutics Dualitas Therapeutics, Inc. is a biotechnology company pioneering next-generation bispecific antibody (BsAb) therapies for immunology and inflammation (I&I). Dualitas' portfolio, built from
More news about: Dualitas Therapeutics
Sep 16, 2025, 07:00 ET Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion
gastrointestinal tumors where patients desperately need treatment options." About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated promising results
More news about: Oncolytics Biotech® Inc.
Sep 16, 2025, 07:00 ET Novella Launches Potent Whole-Cell Strawberry Ingredient at SSW
About NovellaNovella Innovative Technology, Ltd. is a biotechnology company pioneering fruit- and vegetable-derived cell complexes for clean, intelligent, and sustainable wellness solutions. Leveraging its proprietary
More news about: Novella
Sep 16, 2025, 05:45 ET BIOVAXYS ANNOUNCES CLOSING OF UNSECURED CONVERTIBLE DEBENTURE OFFERING
receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about
More news about: BioVaxys Technology Corp.
Sep 15, 2025, 16:30 ET WesternU researchers show Osteopathic Manipulative Treatment improves efficacy of COVID-19 vaccine
Calif. and Lebanon, Ore., is an independent nonprofit health professions university, conferring degrees in biotechnology and pharmaceutical sciences, dental medicine, medical sciences, nursing, optometry, osteopathic medicine, pharmacy, physical therapy, physician
More news about: Western University of Health Sciences
Sep 15, 2025, 16:01 ET Innocan Pharma's Poster on its Liposomal Synthetic CBD Technology Generates Interest at PAINWeek Conference
/PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that its LPT-CBD poster presentation, delivered by Dr. Joseph V. Pergolizzi, Jr.,
More news about: Innocan Pharma Corporation
Sep 15, 2025, 16:01 ET Innocan Pharma's Poster on its Liposomal Synthetic CBD Technology Generates Interest at PAINWeek Conference
2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that its LPT-CBD poster presentation, delivered by Dr. Joseph V. Pergolizzi, Jr.,
More news about: Innocan Pharma Corporation
Sep 15, 2025, 12:50 ET Tethered Drone Market is projected to reach US$2,378.12 million by 2031 at CAGR of 29.3% | The Insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact
More news about: The Insight Partners
Sep 15, 2025, 12:48 ET Diphtheria Tetanus Pertussis (DTP) Vaccine Market Driven by Rising Immunization Programs and Advancements in Healthcare Infrastructure - Market Research Intellect
The DTP Vaccine Market is undergoing transformation due to technological advancements in vaccine research, formulation, and production. Modern biotechnology has enabled the development of safer, more effective, and combination vaccines that reduce the number of injections required for children. Advanced
More news about: Market Research Intellect
Sep 15, 2025, 12:19 ET Butadiene Market Size & Share to Surpass USD 70.95 Billion by 2035, Growing at a CAGR 6.55% | Vantage Market Research
market research reports and actionable intelligence across healthcare, biotechnology, and advanced cell therapies. Our globally recognized insights empower stakeholders to make informed decisions, anticipate trends, and capitalize
More news about: Vantage Market Research
Sep 15, 2025, 12:12 ET Rubin Rudman Partners Michael Riseberg and Theodore Folkman Named to 2026 Lawdragon 500 Leading Litigators in America
Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; regulated industries, public entities and municipalities; insurance companies and their insureds; educational
More news about: Rubin Rudman
Sep 15, 2025, 11:37 ET Racing Gasoline Market is Projected to Reach US$538.85 Million by 2031 at CAGR of 4.4% | The Insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials Contact
More news about: The Insight Partners
Sep 15, 2025, 11:13 ET Cancer Gene Therapy Market Size Worth US$ 19.97 Billion by 2033, with a 19.8% CAGR Growth, Report by DataM Intelligence
international partnerships, as seen at the 2023 ESGCT Congress in Brussels. The UK market is propelled by advancements in biotechnology, increased R&D investment, favorable regulations, and rising cancer cases. Collaborations between academic institutions and biotech firms, along
More news about: DataM Intelligence 4 Market Research LLP
Sep 15, 2025, 10:01 ET Made Scientific and Basilard BioTech Announce Technology Partnership to Advance Ex Vivo Gene Delivery for T Cell and iPSC Therapies
South Korea, a global leader in the pharmaceutical and biotechnology sectors. About Basilard BioTechBasilard BioTech is a Southern California-based biotechnology company revolutionizing the engineering of cell-based therapies. The
More news about: Made Scientific, Inc.
Sep 15, 2025, 09:30 ET HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor
Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH), congratulates its partner BioAge Labs, Inc. ("BioAge", NASDAQ: BIOA), a clinical-stage biotechnology company based in Emeryville, CA, USA, on the initiation of a Phase 1 clinical study of BGE-102, a novel, potent
More news about: HitGen Inc.
Sep 15, 2025, 09:07 ET Curie Co and Microban International Partner to Advance Preservation Solutions for Cleaning, Paints and Coatings
Sept. 15, 2025 /PRNewswire/ -- Curie Co, an ingredient innovator leveraging biotechnology and conscious chemistry, has partnered with Microban International, a global leader in antimicrobial and odor-control technologies, to deliver next-generation
More news about: Microban International
Sep 15, 2025, 09:00 ET MLAB Biosciences Appoints Dr. Edward M. Kaye as Chair of Scientific Advisory Board
NEEDHAM, Mass., Sept. 15, 2025 /PRNewswire/ -- MLAB Biosciences, a biotechnology company pioneering novel therapies for neuromuscular disease, today announced the appointment of Edward M. Kaye,
More news about: MLAB Biosciences
Sep 15, 2025, 08:00 ET Matica Bio Secures Commercial Manufacturing Deal with U.S. Biotech Company
for complex CGT programs in a continuously evolving market governed by strict regulatory requirements." About Matica Biotechnology, Inc.Matica Biotechnology is a viral vector Contract Development and Manufacturing Organization (CDMO) that leverages advanced technologies at its purpose-built
More news about: Matica Biotechnology, Inc.
Sep 15, 2025, 08:00 ET Lipella Pharmaceuticals to Present at Zacks SCR Life Sciences Virtual Investor Forum and Report Final Phase 2a Results in Oral Lichen Planus
Sept. 15, 2025 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (OTC: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company transforming care with innovative mucosal delivery solutions, today announced that Jonathan Kaufman, Chief
More news about: Lipella Pharmaceuticals Inc.
Sep 15, 2025, 08:00 ET Argo Biopharma Receives IND Approval from NMPA for Phase II Clinical Trial of siRNA Therapy, BW-40202, for the Treatment of PNH
effective, durable, safer, and more manageable treatment options. About Argo Biopharma Argo Biopharma is a clinical-stage biotechnology company committed to developing next-generation RNAi therapeutics to provide better treatment options for patients worldwide. The company has established
More news about: Argo Biopharmaceutical Co., Ltd.
Sep 15, 2025, 08:00 ET AuraVax Therapeutics Inc. receives grant for viral challenge study of new broad acting host-directed therapeutic
Joseph Sullivan, AuraVax's CEO. About AuraVax AuraVax Therapeutics, Inc. (AuraVax) is a privately held biotechnology company developing airway products based on our NanoSTING platform for the treatment and prevention of respiratory infections. NanoSTING activates
More news about: AuraVax Therapeutics Inc.
Sep 15, 2025, 07:30 ET Abzena Enhances AbZelectPRO™ Cell Line Offering with New GS Knockout Platforms
abzena.com. About ProteoNicProteoNic is a privately held biotechnology company with offices in Leiden, The Netherlands. The company specializes in advanced cell line generation and viral
More news about: Abzena
Sep 15, 2025, 07:00 ET New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)
Sept. 15, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today new data from the APEX study of KSI-101
More news about: Kodiak Sciences Inc.
Sep 15, 2025, 07:00 ET Former Leaders of Thorne HealthTech and Tempus Launch Brain Health and Wellness Company BEVIMI at Inaugural CG Well Summit
HealthTech, where he led the company through 15 years of expansion. Prior to that, he was a private investor who served on various healthcare and biotechnology company boards of directors, including Progenics Pharmaceuticals. Earlier in his career, Jacobson was a Partner and Co-Head of the Liquid Capital
More news about: BEVIMI
Sep 15, 2025, 06:00 ET Gyala Therapeutics unveils first-in-class CAR-T therapy targeting CD84 showing strong preclinical efficacy in hard-to-treat leukemias
Sept. 15, 2025 /PRNewswire/ -- Gyala Therapeutics, a biotechnology company developing next-generation immunotherapies for blood cancers, announced the publication of preclinical results demonstrating the efficacy
More news about: Gyala Therapeutics